Clinical Alignment Summary: COVID-19 Discharge Guidance

The purpose of this summary is to display how clinical guidance from different organizations is aligned in this topic area.

### Prior to Discharge

- Identify the patient’s psychosocial environment and post-discharge needs early in their hospital course. Engage with case management, other hospital disciplines/teams, and local departments of public health, if needed, to create a safe discharge plan (1,2,3).
  - Decide if patient will require Isolation instructions or Test Based Strategy prior to discharge (1,2). Most patients will not require repeat COVID-19 testing (1). Refer to Isolation Precautions Summary.
  - Verify contact information for patient and primary community support person and adequate support and resources at home (3).
- Provide enough medication to last the duration of isolation period and two surgical masks (3).

### Decision to Discharge

**Symptomatic, uncomplicated patients should self-isolate at home until they meet all three criteria:** (1,4,5)

- Fever resolved without antipyretic for at least 3 days
- Improved respiratory symptoms
- At least 10-14 days have passed since first symptoms appeared (if asymptomatic, 10 days after 1st positive test)

- Repeat testing NOT required to achieve resolution of infection status (1,4).
- Two negative COVID-19 tests over 24 hours apart required for discharge (5).
- Infection control approval is required to resolve infection status/ isolation orders (5).

### Establish a Discharge Plan

**ALL PATIENTS**

- If the patient has a PCP, follow-up with PCP via phone or telemedicine in 2-5 days. If no PCP follow-up may be facility specific. Some hospitals have established teams to follow up on patients (1). Instruct patient to inform PCP of COVID-19 status for care coordination needs (3).
- Ensure patient has a safe, private method of transportation to their discharge destination (2,3).

**DISCHARGE TO PRIVATE RESIDENCE**

- Contact local department of public health/ hospital infection control to determine safest feasible post-hospital discharge location (2).
- Establish return criteria and instructions in the case that symptoms return or worsen (1,2).

**PATIENTS EXPERIENCING HOMELESSNESS**

- Coordinate with case management to establish a discharge plan (1,2).
- Consult infection control if placement is delayed or isolation is not feasible (1); Refer to Isolation Precautions Summary.
- Establish follow up communication (1).
- Establish return criteria and instructions in the case that symptoms return or worsen (1).

**DISCHARGE TO INSTITUTIONAL SETTINGS**

- Work closely with case manager to ensure proper placement (1).
- Determine the institution’s ability to isolate patients and when necessary consult infection control and case management to take patient off precautions (1,4). Refer to Isolation Precautions Summary.

### Safe Discharge Considerations

- Confirm patient can manage ADLs independently or with available home support (2,3)
- Ensure the patient has arrangements for safely obtaining medications, grocery shopping, and other necessary ADLs (2,3).
- Ensure home health needs (oxygen, thermometers, etc.) are met (1,2).
- Provide information/resources regarding the infectious risk patient poses to household contacts and others (1,2,3,4).
- Consider unique discharge coordination if other members of household are hospitalized simultaneously (2).
Patients who required ICU care during their hospitalization, are severely immunocompromised or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications,

**Association of American Medical Colleges Disclaimer:** This clinical guidance is provided for informational purposes only and is intended to supplement, but not overrule, the judgment of a qualified medical professional. All information is meant for use by clinicians, not the general public, and does not constitute provision of medical advice. This information is being made available in the context of the public health emergency related to the coronavirus (COVID-19) and has not been subjected to review, investigation, or testing that typically would be performed in a non-emergent situation. This information is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment and should be adapted to the patient’s specific needs, available resources, and any other unique circumstances. Neither the AAMC, nor any contributor, makes any representations or warranties, express or implied, with respect to the information provided herein or to its use.

Version 1.2 8/10/20